Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Phase 1
30
about 4.1 years
18+
1 site in MO
About this study
Researchers are testing whether adding CYT107 to standard treatment after autologous hematopoietic cell transplant can help clear tumors, improve immune function, and reduce infections in people with multiple myeloma. The trial will compare patients who receive CYT107 plus melphalan and AHCT to those who only receive melphalan and AHCT.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Melphalan
- 2.Take Recombinant glycosylated human interleukin-7
- 3.Undergo Autologous hematopoietic cell transplant
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
melphalan
injection, intravenous
Primary: Rate of non-hematologic grade ≥3 CYT107 treatment-related AEs (excluding expected transplant-related AEs or AEs attributed to melphalan and ASCT) according to CTCAE v5
Secondary: Rate of response by IMWG of ≥ complete response (CR)
surgery
Oncology